Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold.

Trial Profile

Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; First in man
  • Acronyms FANTOM-1
  • Sponsors REVA Medical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2015 Results presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference, as per REVA Medical media release.
    • 28 Jul 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top